Document:

exbit101.htm

 

 SETTLEMENT AGREEMENT AND RELEASE

 

This SETTLEMENT AGREEMENT AND RELEASE (“Agreement”) is entered into between Plaintiff Bio-Mimetics, Inc. (“Plaintiff”) and Defendant Columbia Laboratories, Inc. (“Defendant”) (together, the “Parties”).

 

 

 

RECITALS

 

WHEREAS, Plaintiff filed Civil Action No. 1:07-cv-12389-RGS (the “Lawsuit”) in the U.S. District Court for the District of Massachusetts on December 28, 2007, against the Defendant, alleging various causes of action, which led to appeals and cross-appeals in the U.S. Court of Appeals for the Federal Circuit (Appeal Nos. 2010-1535, -1537 and 2011-1062) (the “Appeals”);

 

WHEREAS, Defendant denies each and every one of the Plaintiff’s allegations in the Lawsuit and the Appeals;

 

WHEREAS, the Parties desire to settle and resolve the Lawsuit, the Appeals, and any and all disputes and claims that exist, which have been or could have been asserted among them;

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

 

 

 

TERMS OF AGREEMENT

 

 

	1. 	INCORPORATION OF RECITALS. The Parties hereby incorporate the above recitals. 
	2.	
EFFECTIVENESS OF AGREEMENT. This Agreement shall become effective immediately upon execution by all of the Parties. The date on which the latter of the Parties executes the Agreement shall be the Effective Date. 

	3. 	CASH PAYMENT. Within ten business days after the dismissals described in paragraph 3, the Defendant will pay to Plaintiff $1.8 million (USD) by cashiers check made out to Bio-Mimetics, Inc. 
	4.	
STIPULATION OF DISMISSAL. Within ten business days after executing this Agreement, the Parties will file an executed Stipulation of Dismissal with Prejudice of the Lawsuit against the Defendant in the U.S. District Court for the District of Massachusetts, and the Parties will file one or more (as needed to effect such dismissals) executed Joint Stipulations of Dismissal with Prejudice of the Appeals in the U.S. Court of Appeals for the Federal Circuit.

	
5.

	

RELEASES. Except for as otherwise provided in this Agreement, the Parties release each other and their agents, attorneys, officers, directors, affiliates, and employees of and from all claims and causes of action that were asserted in the Lawsuit and Appeals and from all known or unknown claims, actions, causes of actions, lawsuits, proceedings, adjustments, offsets, contracts, obligations, liabilities, controversies, damages, rights, demands, debts, costs, expenses, attorneys fees, losses, and recovery of any nature whatsoever, that could have been asserted as of the date of this Agreement including, but not limited to, any claims based on (a) the 1989 Asset Purchase, License and Option Agreement and (b) the March 2, 1993 amendment to that agreement. This release includes any and all disputes between the parties that relate to Columbias agreements with Watson Pharmaceuticals concerning progesterone products. 

	6.	
CANCELLATION OF THE 1989 ASSET PURCHASE, LICENSE AND OPTION AGREEMENT AND THE 1993 AMENDMENT THERETO. The November 22, 1989 Asset Purchase, License and Option Agreement and the March 2, 1993 amendment thereto are hereby cancelled, void, and of no further effect. 

	7.	
NO ADMISSION. Neither this Agreement nor any payment hereunder shall be deemed to be, and shall not be cited or referred to as, an admission of liability by Plaintiff or Defendant.

	8.	
GOVERNING LAW. The Agreement shall be construed and integrated in accordance with the laws of the State of Delaware, without regard to any choice of law principles.

	9.	
DISPUTES. The parties shall attempt in good faith to resolve any disputes concerning this agreement before filing a lawsuit. 

	10.	
NOTICES. Any notices pursuant to this Agreement shall be provided to the other Party as follows:

 

 

 

	 TO BIO-MIMETICS, INC.:  	
Robert J. Silverman 

Foley & Lardner, LLP 

111 Huntington Ave. Boston, MA  02199

(617) 342-4001

 

	 TO COLUMBIA LABORATORIES, INC.: 	
Charles B. Klein 

Winston & Strawn LLP 

1700 K Street, N.W. 

Washington, DC  20006

(202) 282-5977

 

	
11.  

	
INTERPRETATION AND CONSTRUCTION. This Agreement shall be interpreted and construed without any presumption that its provisions are to be construed against the drafter of this Agreement.  The Parties and their attorneys fully and equally participated in the preparation, negotiation, review, and approval of this Agreement.

	
12.  

	
AMENDMENTS AND WAIVERS. This Agreement may be amended only by a writing signed by all Parties.  Compliance with a provision of this Agreement may be waived only by a writing signed by the Party waiving compliance and having capacity to waive such compliance.

	
13.  

	
BINDING AGREEMENT. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their representatives, predecessors, successors, heirs, survivors, personal representatives, and assigns.

	
14.  

	
SEVERABILITY. In the event that any part of this Agreement is found to be illegal, unenforceable, void, or in violation of public policy by any court of competent jurisdiction, it shall be deemed severable from the remainder of this Agreement and shall in no way affect any other condition, covenant or other provision of this Agreement.

	
15.  

	
EXECUTION OF AGREEMENT. Each Party warrants and represents that its undersigned representative has the capacity, right, and authority to execute this Agreement.

	
16.  

	
COUNTERPARTS. This Agreement may be executed in counterparts, all of which together shall be one instrument and all of which shall be considered duplicate originals.

	
17.  

	
ENTIRE AGREEMENT. This Agreement embodies all of the terms and conditions of the Settlement Agreement and Release described herein, and it is the complete agreement among the Parties.  This Agreement supersedes and takes precedence over any communication, whether oral or written.  The Parties acknowledge they have not relied on any promise, representation, or express or implied warranty outside of this Agreement.

 

  

  

  

IN WITNESS WHEREOF, and in agreement herewith, the Parties have executed and delivered this Agreement as of the effective date.

 

	
  

	
By:/S/ George A. Stevens    Dated: 11.24.10 

      Bio-Mimetics, Inc.

 

	
  

	
By:/S/ Frank C. Condella, Jr.   Dated: Dec. 3, 2010

     Columbia Laboratories, Inc.stjude106104_ex4-1.htm - Generated by SEC Publisher for SEC Filing

 

 

 

Exhibit 4.1

 

 

 

THIRD SUPPLEMENTAL INDENTURE

ST. JUDE MEDICAL, INC.

AND

U.S. BANK NATIONAL ASSOCIATION,

AS TRUSTEE

Third Supplemental Indenture

Dated as of December 6, 2010

Supplementing the Indenture

Dated as of July 28, 2009

 

 

 

 

 

 

THIRD SUPPLEMENTAL INDENTURE, dated as of December 6, 2010 (this “Third
Supplemental Indenture”), between St. Jude Medical, Inc., a corporation
duly organized and existing under the laws of Minnesota (herein called the “Company”),
and U.S. Bank National Association, as Trustee (herein called “Trustee”);

RECITALS:

WHEREAS,
the Company and the Trustee have heretofore executed and delivered an
Indenture, dated as of July 28, 2009 (the “Base Indenture” and, together
with the Third Supplemental Indenture, the “Indenture”), providing for
the issuance from time to time of the Company’s debentures, notes or other
evidences of indebtedness (herein and therein called the “Securities”),
to be issued in one or more series as provided in the Base Indenture; 

WHEREAS,
Section 12.1 of the Base Indenture permits the Company and the Trustee to enter
into an indenture supplemental to the Base Indenture to establish the form and
terms of any series of Securities; 

WHEREAS,
Section 2.1 of the Base Indenture permits the form of Securities of any series
to be established in an indenture supplemental to the Base Indenture; 

WHEREAS,
Section 3.1 of the Base Indenture permits certain terms of any series of
Securities to be established pursuant to an indenture supplemental to the Base
Indenture; 

WHEREAS,
pursuant to Sections 2.1 and 3.1 of the Base Indenture, the Company desires to
provide for the establishment of a new series of Securities under the Base
Indenture, the form and substance of such Securities and the terms, provisions
and conditions thereof to be set forth as provided in the Base Indenture and
this Third Supplemental Indenture; and

WHEREAS,
all things necessary to make this Third Supplemental Indenture a valid
agreement of the Company, in accordance with its terms, have been done.

NOW,
THEREFORE, for and in consideration of the foregoing and the purchase of the
Securities of the new series established by this Third Supplemental Indenture
by the holders thereof (the “Holders”), it is mutually agreed, for the
equal and proportionate benefit of all such Holders, as follows: 

ARTICLE 1

 

Definitions and Other Provisions of General Application

Section
1.01             
Relation to Base
Indenture. This Third Supplemental Indenture constitutes a part
of the Base Indenture (the provisions of which, as modified by this Third
Supplemental Indenture, shall apply to the Notes (as defined in Section 2.01))
in respect of the Notes but shall not modify, amend or otherwise affect the
Base Indenture insofar as it relates to any other series of Securities or
modify, amend or otherwise affect in any manner the terms and conditions of the
Securities of any other series. 

 

1

 

 

 

Section
1.02             
Definitions.  For all
purposes of this Third Supplemental Indenture, the capitalized terms used
herein (i) which are defined in this Section 1.02 have the respective meanings
assigned hereto in this Section 1.02 and (ii) which are defined in the
Base Indenture (and which are not defined in this Section 1.02) have the
respective meanings assigned thereto in the Base Indenture.  For all purposes
of this Third Supplemental Indenture: 

(a)                
Unless the context otherwise
requires, any reference to an Article or Section refers to an Article or
Section, as the case may be, of this Third Supplemental Indenture; 

(b)                
The words “herein,” “hereof” and
“hereunder” and words of similar import refer to this Third Supplemental
Indenture as a whole and not to any particular Article, Section or other
subdivision; 

(c)                
Headings are for convenience of
reference only and do not affect interpretations; and 

(d)                
The terms defined in this
Section 1.02(d) have the meanings assigned to them in this Section and
include the plural as well as the singular:

“Interest
Payment Date” has the meaning set forth in Section 2.01(d). 

“Interest
Period” has the meaning set forth in Section 2.01(d). 

“Maturity
Date” has the meaning set forth in Section 2.01(c). 

“Notes”
has the meaning set forth in Section 2.01(a). 

ARTICLE 2

 

General Terms and Conditions of the Notes 

Section 2.01             
Terms of Notes.  Pursuant
to Sections 2.1 and 3.1 of the Base Indenture, there is hereby established a
new series of Securities, the terms of which shall be as follows: 

(a)                
Designation.  There is hereby authorized and established a new
series of  Securities under the Base Indenture, known and designated as the
“2.500% Senior Notes due 2016” (the “Notes”) of the Company.  This series
of Notes is unlimited in aggregate principal amount.  The initial aggregate
principal amount of the Notes to be issued under this Third Supplemental
Indenture shall be $500,000,000.  Any additional amounts of the Notes to be
issued shall be set forth in a Company Order.

(b)                
Form and Denominations.  The Notes will be issued only in fully registered
form, and the authorized denominations of the Notes shall be $1,000 principal
amount and any integral multiple of $1,000 in excess thereof. The Notes will
initially be issued in the form of one or more Global Securities substantially
in the form of Exhibit A attached hereto, with such modifications
thereto as may be approved by the authorized officer executing the same.  The
Notes will be denominated in U.S. dollars and payments of principal, premium,
if any, and interest will be made in U.S. dollars. 

 

2

 

 

 

(c)                
Maturity Date.  The Stated Maturity of principal for the Notes
shall be payable in full on January 15, 2016 (the “Maturity Date’’).

(d)                
Interest.  Interest payable on any Interest Payment Date (as
defined below), the Maturity Date, or if applicable, the Redemption Date (as
determined in accordance with Section 4.2 of the Base Indenture) shall be the
amount accrued from, and including, the immediately preceding Interest Payment
Date in respect of which interest has been paid or duly provided for (or from
and including the original issue date of December 6, 2010, if no interest
has been paid or duly provided for with respect to the Notes) to but excluding
such Interest Payment Date, Maturity Date or, if applicable, Redemption Date,
as the case may be (each, an “Interest Period”).  The Notes will bear
interest at the rate of 2.500% per year from the original issue date thereof to
the respective Maturity Date.  Interest on the Notes shall be payable
semi-annually in arrears on January 15 and July 15 of each year,
beginning on July 15, 2011 (each such date, an “Interest Payment Date”). 
The amount of interest payable for any semi-annual Interest Period will be
computed on the basis of a 360-day year consisting of twelve 30-day months.  In
the event any Interest Payment Date on or before the Maturity Date falls on a
day that is not a Business Day, the interest payment due on that date will be
postponed to the next day that is a Business Day and no interest shall accrue
as a result of such postponement. 

In the event the Maturity Date or a Redemption Date
for any Note falls on a day that is not a Business Day, then the related
payments of principal, premium, if any, and interest may be made on the next
succeeding date that is a Business Day (and no additional interest will
accumulate on the amount payable for the period from and after the Maturity
Date for such Note).  Interest due on the Maturity Date or a Redemption Date
(in each case, whether or not an Interest Payment Date) will be paid to the
Person to whom principal of such Notes is payable. 

(e)                
Sinking Fund; Holder Repurchase
Right.  The Notes shall not be
subject to any sinking fund or analogous provision or be redeemable at the option
of the Holders. 

(f)                 
Forms.  The Notes shall be substantially in the form of Exhibit A
attached hereto, with such modifications thereto as may be approved by the
authorized officer executing the same. 

(g)                
Appointment of Agent. The Trustee will initially be the Registrar and
Paying Agent with respect to the Notes.

(h)                
Defeasance.  Until the applicable Maturity Date, the Notes will
be subject to Sections 11.2 and 11.3 of the Base Indenture. 

(i)             Further Issues.  The Company
may from time to time, without the consent of the Holders of Notes, issue
additional Notes.  Any such additional Notes will have the same ranking,
interest rate, maturity date and other terms as the Notes.  Any such additional
Notes, together with the Notes herein provided for, will constitute a single
series of Securities under the Indenture. 

 

3

 

 

 

ARTICLE 3

 

EVENTS OF DEFAULT

Section 3.01              Events of Default.  Pursuant to Section 3.1 of the Base Indenture, the term “Event of Default” with respect to the Notes shall include, in addition to those otherwise set forth in Section 7.1 of the Base Indenture, the following:  the occurrence with respect to any Debt of the Company in an aggregate principal amount of $75,000,000 or more of (a) an event of default that results in such Debt becoming due and payable prior to its scheduled maturity (after giving effect to any applicable grace period) or (b) the failure to make any payment when due (including any applicable grace period) which results in the acceleration of the maturity of such Debt, in each case without such acceleration having been rescinded, annulled or otherwise cured.

ARTICLE 4

 

REDEMPTION OF THE NOTES

Section 4.01              Optional Redemption by Company.  The Notes may be redeemed at the option of the Company on the terms and conditions set forth in the form of Note as set forth as Exhibit A.

ARTICLE 5

 

CHANGE OF CONTROL

Section 5.01              Offer to Purchase Upon Change of Control Triggering Event.  Upon the occurrence of a Change of Control Triggering Event (as defined in the form of Note set forth as Exhibit A), and unless the Company has exercised its option to redeem the Notes pursuant to Section 4.01, the Company shall be required to make an offer to each Holder of the Notes to repurchase all or any part (equal to $1,000 or an integral multiple of $1,000 in excess thereof) of that Holder’s Notes on the terms and conditions set forth in the form of Note set forth as Exhibit A.

ARTICLE 6

 

Miscellaneous

Section 6.01              Relationship to Existing Base Indenture.  This Third Supplemental Indenture is a supplemental indenture within the meaning of the Base Indenture.  The Base Indenture, as supplemented and amended by this Third Supplemental Indenture, is in all respects ratified, confirmed and approved and, with respect to the Notes, the Base Indenture, as supplemented and amended by this Third Supplemental Indenture, shall be read, taken and construed as one and the same instrument.

Section 6.02              Modification of The Existing Base Indenture.  Except as expressly modified by this Third Supplemental Indenture, the provisions of the Base Indenture shall govern the terms and conditions of the Notes. 

 

4

 

 

 

Section 6.03              Governing Law.  This Third Supplemental Indenture shall be governed by and construed in accordance with the laws of the State of New York.

Section 6.04              Counterparts.  This Third Supplemental Indenture may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument. 

Section 6.05              Trustee Makes No Representation.  The recitals contained herein are made by the Company and not by the Trustee, and the Trustee assumes no responsibility for the correctness thereof. The Trustee makes no representation as to the validity or sufficiency of this Third Supplemental Indenture (except for its execution thereof and its certificates of authentication of the Notes). 

Section 6.06         Separability.  In case any provision in the Base Indenture, this Third Supplemental Indenture or the Notes shall for any reason be held to be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

[Signature page follows]

 

 

 

 

5

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Third Supplemental Indenture to be duly executed and attested all as of the day and year first above written. 

Dated: December 6, 2010

 

 

	
 

	
ST. JUDE MEDICAL, INC.,

	
 

	
as Issuer

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
By:

	
/s/ John Heinmiller

	
 

	
 

	
Name:

	
John C. Heinmiller

	
 

	
 

	
Title:

	
Executive Vice President and Chief Financial Officer

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
U.S. BANK NATIONAL ASSOCIATION,

	
 

	
as Trustee

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
By:

	
/s/ Raymond S. Haverstock

	
 

	
 

	
Name:

	
Raymond S. Haverstock

	
 

	
 

	
Title:

	
Vice President

 

 

                                                                                                        

 

 

 

EXHIBIT A

[Form of Senior Notes]

THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE OF THE DEPOSITARY WHICH MAY BE TREATED BY THE COMPANY, THE TRUSTEE OR ANY AGENT THEREOF AS OWNER AND HOLDER OF THIS SECURITY FOR ALL PURPOSES. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 

ST. JUDE MEDICAL, INC.

	
 

	
 

	
 

	
No. ___

	
 

	
CUSIP NO. 790849 AH6

$_________

Interest.  St. Jude Medical, Inc., a corporation duly incorporated and subsisting under the laws of the State of Minnesota (herein called the “Company”, which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to Cede & Co., or registered assigns, the principal sum of  ___________ DOLLARS ($_________), as revised by the Schedule of Increases or Decreases in Global Security attached hereto, on January 15, 2016 and to pay interest thereon from December 6, 2010 or from the most recent Interest Payment Date to which interest has been paid or duly provided for, semi-annually on January 15 and July 15 in each year, commencing July 15, 2011, at the rate of 2.500% per annum, until the principal hereof is paid or made available for payment. 

A-1

 

 

 

 

Method of Payment.  The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on the Regular Record Date for such interest, which shall be the January 1 or July 1 (whether or not a Business Day), as the case may be, next preceding such Interest Payment Date. Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in said Indenture. 

Payment of the principal of (and premium, if any) and interest on this Security will be made at the office or agency of the Trustee maintained for that purpose in New York, New York, in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts. 

Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place. 

Authentication.  Unless the certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

 

                                                                            A-2                                                                                                     

 

IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its corporate seal. 

 

	
Dated:  December 6, 2010

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
ST. JUDE MEDICAL, INC.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
By:

	
 

	
 

	
 

	
 

	
Name:

	
 

	
 

	
 

	
Title:

	
 

 

 

                                                                             A-3                                                                             

 

[FORM OF CERTIFICATION OF AUTHENTICATION]

CERTIFICATE OF AUTHENTICATION

This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture.

 

	
 

	
U.S. BANK NATIONAL ASSOCIATION,

	
 

	
as Trustee

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
By:

	
 

	
 

	
 

	
 

	
Authorized Signatory

 

 

A-4

 

[Form of Reverse of Note] 

Indenture.  This Security is one of a duly authorized issue of securities of the Company (herein called the “Securities”), issued and to be issued in one or more series under an Indenture, dated as of July 28, 2009 (herein called the “Base Indenture”, which term shall have the meaning assigned to it in such instrument), as supplemented by a Third Supplemental Indenture dated as of December 6, 2010 (herein called the “Third Supplemental Indenture”, and together with the Base Indenture, the “Indenture”), between the Company and U.S. Bank National Association, as Trustee (herein called the “Trustee”, which term includes any successor trustee under the Indenture), and reference is hereby made to the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered.  This Security is one of the series designated on the face hereof, initially limited in aggregate principal amount to $500,000,000.  The Company may at any time issue additional securities under the Indenture in unlimited amounts having the same terms as the Securities.  

Optional Redemption.  The Securities of this series are subject to redemption at the Company’s option,  at any time and from time to time, in whole or in part, upon not less than 30 nor more than 60 days’ notice mailed to each Holder of Securities to be redeemed at his address as it appears in the records of the Registrar, on any date prior to their Stated Maturity at a Redemption Price equal to the greater of (i) 100% of the principal amount of such Securities to be redeemed, plus accrued and unpaid interest thereon to the Redemption Date or (ii) as determined by an Independent Investment Banker (as defined below), the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the Redemption Date) discounted to the Redemption Date on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined below), plus 15 basis points, plus accrued and unpaid interest thereon to the Redemption Date; provided that unless the Company defaults in payment of the Redemption Price, on or after the Redemption Date, interest will cease to accrue on the Securities or portions thereof called for redemption.

For purposes of determining the optional redemption price, the following definitions are applicable:

“Treasury Rate” means, with respect to any Redemption Date, the rate per annum equal to the semi-annual equivalent yield to maturity of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such Redemption Date.  The semi-annual equivalent yield to maturity of the Comparable Treasury Issue will be computed as of the third business day immediately preceding the Redemption Date.  

“Comparable Treasury Issue” means the United States Treasury security or securities selected by the Independent Investment Banker as having a maturity comparable to the remaining term of the Securities to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Securities. 

 

A-5

 

 

“Comparable Treasury Price” means, with respect to any Redemption Date, (1) the average of the Reference Treasury Dealer Quotations for such Redemption Date, after excluding the highest and lowest Reference Treasury Dealer Quotations, or (2) if the Independent Investment Banker obtains fewer than four Reference Treasury Dealer Quotations, the average of all Reference Treasury Dealer Quotations so received.

“Independent Investment Banker” means the Reference Treasury Dealer appointed by the Company.

“Reference Treasury Dealer” means Merrill Lynch, Pierce, Fenner & Smith Incorporated and a Primary Treasury Dealer (as defined herein) selected by Wells Fargo Securities, LLC, and their successors and two other nationally recognized investment banking firms; provided, however, that, if the foregoing shall cease to be a primary U.S. Government securities dealer in New York City (a “Primary Treasury Dealer”), the Company shall substitute therefor another nationally recognized investment banking firm that is a Primary Treasury Dealer. 

“Reference Treasury Dealer Quotations” means, with respect to each Reference Treasury Dealer and any Redemption Date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue for the Securities (expressed in each case as a percentage of its principal amount) quoted in writing to the Independent Investment Banker by such Reference Treasury Dealer at 3:30 p.m., New York City time, on the third Business Day preceding such Redemption Date. 

In the event of redemption of this Security in part only, a new Security or Securities of this series and of like tenor for the unredeemed portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof.

Change of Control.  If a Change of Control Triggering Event occurs, unless the Company has exercised its right to redeem the Securities as described above, it will be required to make an offer to repurchase all, or any part (equal to $1,000 or an integral multiple thereof), of each Holder’s Securities pursuant to the offer described below (the “Change of Control Offer”) on the terms set forth herein.  In the Change of Control Offer, the Company will be required to offer payment in cash equal to 101% of the aggregate principal amount of Securities repurchased plus accrued and unpaid interest, if any, on the Securities repurchased, to the date of purchase (the “Change of Control Payment”).

Within 30 days following any Change of Control Triggering Event or, at the Company’s option, prior to any Change of Control but after the public announcement of the pending Change of Control, the Company will be required to mail a notice to Holders of Securities describing the transaction or transactions that constitute or may constitute the Change of Control Triggering Event and offering to repurchase the Securities on the date specified in the notice, which date will be no earlier than 30 days and no later than 60 days from the date such notice is mailed (the “Change of Control Payment Date”), pursuant to the procedures required herein and described in such notice.  The Company must comply with the requirements of Rule 14e-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the Securities as a result of a Change of Control Triggering Event.  To the extent that the provisions of any securities laws or regulations conflict with the Change of Control provisions herein, the Company will be required to comply with the applicable securities laws and regulations and will not be deemed to have breached its obligations under the Change of Control provisions herein by virtue of such conflicts. 

 

A-6

 

 

On the Change of Control Payment Date, the Company will be required, to the extent lawful, to: 

(a)           accept for payment all Securities or portions of Securities properly tendered, and not validly withdrawn, pursuant to the Change of Control Offer; 

(b)           deposit with the Paying Agent an amount equal to the Change of Control Payment in respect of all Securities or portions of Securities properly tendered and not validly withdrawn; and 

(c)           deliver or cause to be delivered to the Trustee the Securities properly accepted together with an Officers’ Certificate stating the aggregate principal amount of Securities or portions of Securities being purchased by the Company. 

The Paying Agent will be required to mail promptly to each Holder who properly tendered Securities the purchase price for such Securities and the Trustee will be required to authenticate and mail (or cause to be transferred by book entry) promptly to each such Holder a new Security equal in principal amount to any unpurchased portion of the Securities surrendered, if any; provided that each new Security will be in a principal amount of $1,000 or an integral multiple thereof. 

For purposes of the foregoing discussion of a repurchase at the option of Holders, the following definitions are applicable: 

“Capital Stock” means the capital stock of every class whether now or hereafter authorized, regardless of whether such capital stock shall be limited to a fixed sum or percentage with respect to the rights of the holders thereof to participate in dividends and in the distribution of assets upon the voluntary or involuntary liquidation, dissolution or winding up of such corporation. 

“Change of Control” means the occurrence of any of the following:

(a)           the direct or indirect sale, lease, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or more series of related transactions, of all or substantially all of the Company’s assets and the assets of its Subsidiaries, taken as a whole, to any “person” (as that term is used in Section 13(d)(3) of the Exchange Act), other than the Company or one of its Subsidiaries;

(b)           the consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that any “person” (as that term is used in Section 13(d)(3) of the Exchange Act) other than the Company or one of its Subsidiaries, becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of more than 50% of the Company’s then outstanding Voting Stock or other Voting Stock into which the Company’s Voting Stock is reclassified, consolidated, exchanged or changed, measured by voting power rather than number of shares;

 

A-7

 

 

(c)           the first day on which a majority of the Company’s members of its board of directors are not Continuing Directors; or 

(d)           the adoption of a plan relating to the Company’s liquidation or dissolution.

Notwithstanding the foregoing, a transaction will not be considered to be a Change of Control if (a) the Company becomes a direct or indirect wholly-owned subsidiary of a holding company and (b)(x) immediately following that transaction, the direct or indirect holders of the Voting Stock of the holding company are substantially the same as the holders of the Company’s Voting Stock immediately prior to that transaction or (y) immediately following that transaction, no person is the beneficial owner, directly or indirectly, of more than 50% of the Voting Stock of such holding company. 

“Change of Control Triggering Event” means the occurrence of both a Change of Control and a Rating Event.

“Continuing Directors” means, as of any date of determination, any member of the Company’s board of directors who (a) was a member of such board of directors on December 6, 2010 or (b) was nominated for election, elected or appointed to such board of directors with the approval of a majority of the Continuing Directors who were members of such board of directors at the time of such nomination, election or appointment (either by a specific vote or by approval of a proxy statement in which such member was named as a nominee for election as a director).

“Fitch” means Fitch, Inc. and its successors. 

“Investment Grade” means a rating of Baa3 or better by Moody’s (or its equivalent under any successor rating categories of Moody’s), a rating of BBB- or better by S&P (or its equivalent under any successor rating categories of S&P) and a rating of BBB- or better by Fitch (or its equivalent under any successor rating categories of Fitch). 

“Moody’s” means Moody’s Investors Service, Inc., a subsidiary of Moody’s Corporation, and its successors. 

“Rating Agencies” means (a) each of Moody’s, S&P and Fitch; and (b) if any of Moody’s, S&P or Fitch ceases to rate the Securities or fails to make a rating of the Securities publicly available for reasons outside of the Company’s control, a “nationally recognized statistical rating organization” within the meaning of Rule 15c3-1(c)(2)(vi)(F) under the Exchange Act that is selected by the Company (as certified by a resolution of the Company’s board of directors) as a replacement agency for Moody’s, S&P or Fitch, or each of them, as the case may be.

 

A-8

 

 

“Rating Event” means, with respect to the Securities, the rating on the Securities is lowered below Investment Grade by any two of the three Rating Agencies on any date during the period commencing 60 days prior to the public notice of an arrangement that could result in a Change of Control until the end of the 60-day period following public notice of the occurrence of the Change of Control (which 60-day period shall be extended so long as the rating of the Securities is under publicly announced consideration for possible downgrade by any of the Rating Agencies), provided that a Rating Event otherwise arising by virtue of a particular reduction in, or termination of, any rating shall not be deemed to have occurred with respect to a particular Change of Control (and thus shall not be deemed a Rating Event for purposes of the definition of Change of Control Triggering Event hereunder) if the Rating Agency or Rating Agencies ceasing to rate the Securities or making the reduction in rating to which this definition would otherwise apply do not announce or publicly confirm or inform the Trustee in writing at its request that the termination or reduction was the result, in whole or in part, of any event or circumstance comprised of or arising as a result of, or in respect of, the applicable Change of Control (whether or not the applicable Change of Control shall have occurred at the time of the Rating Event).

 

“S&P” means Standard & Poor’s Ratings Services, a division of The McGraw-Hill Companies, Inc., and its successors. 

“Voting Stock” means, with respect to any specified person as of any date, the Capital Stock of such person that is at the time entitled to vote generally in the election of the board of directors of such person. 

The Indenture contains provisions for defeasance at any time of the entire indebtedness of this Security or certain restrictive covenants and Events of Default with respect to this Security, in each case upon compliance with certain conditions set forth in the Indenture, which provisions apply to this Security.  This Security is not subject to repayment at the Holder’s option.

No reference herein to the Indenture and no provision of this Security or the Indenture shall affect or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of, premium, if any, and interest on this Security at the respective due dates, place and rate, and in the Currency herein prescribed.

Default and Remedies.  If an Event of Default with respect to Securities of this series shall occur and be continuing, the principal of the Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture.  

Amendment, Modification and Waiver.  The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the time outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities of each series at the time outstanding, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security.

 

A-9

 

 

Denominations; Transfer and Exchange. As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Security is registrable in the records of the Registrar, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and any premium and interest on this Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Registrar duly executed by, the Holder hereof or the Holder’s attorney duly authorized in writing, and thereupon one or more new Securities of this series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. 

The Securities of this series are issuable only in registered form in denominations of $1,000 and any integral multiple of $1,000 thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal amount of Securities of this series and of like tenor of a different authorized denomination, as requested by the Holder surrendering the same. 

No service charge shall be made to a Holder for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. 

Persons Deemed Owners.  Prior to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary. 

Miscellaneous.  The Indenture and the Securities, including this Security, shall be governed by and construed in accordance with the law of the State of New York. 

All terms used in this Security and not defined herein shall have the meanings assigned to them in the Indenture.

Pursuant to a recommendation promulgated by the Committee on Uniform Security Identification Procedures, the Company has caused “CUSIP” numbers to be printed on the Securities as a convenience to the Holders of the Securities. No representation is made as to the correctness or accuracy of such CUSIP numbers as printed on the Securities, and reliance may be placed only on the other identification numbers printed hereon. 

Unless the certificate of authentication hereon has been executed by or on behalf of the Trustee by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

 

A-10

 

 

ASSIGNMENT FORM 

 

 

FOR VALUE RECEIVED, the undersigned hereby

sells, assigns and transfers unto 

 

 

PLEASE INSERT SOCIAL

SECURITY OR OTHER IDENTIFYING

NUMBER OF ASSIGNEE 

 

________________________________

 

 

	
(Please Print or Typewrite Name and Address, including Zip Code, of Assignee)

	
 

	
 

	
 

	
 

	
 

	
 

	
 the within Security of St. Jude Medical, Inc. and ________________ hereby does irrevocably constitute and appoint

	
 

	
 

	
 

	
 

	
 

	
 

	
Attorney to transfer said Security on the books of the within-named Company with full power of substitution in the premises

	
 

	
 

	
 

	
 

	
 

	
 

	
Dated: 

	
 

 

 

	
Signature

	
 

 

 

NOTICE:  The signature to this assignment must correspond with the name as it appears on the first page of the within Security in every particular, without alteration or enlargement or any change whatever.

 

 

	
Signature

Guaranteed:

	
 

 

NOTICE:  Signature(s) must be guaranteed by an “eligible guarantor institution” that is a member or participant in a “signature guarantee program” (e.g., the Securities Transfer Agents Medallion Program, the Stock Exchange Medallion Program and the New York Stock Exchange Medallion Program).

 

 

A-11

 

 

SCHEDULE OF INCREASES OR DECREASES IN GLOBAL SECURITY

The following increases or decreases in this Global Security have been made:

 

	
Date of

Exchange

	
      

	
Amount of increase in

Principal Amount of

this Global Security

	
      

	
Amount of decrease 

in Principal Amount 

of this Global

Security

	
      

	
Principal Amount of 

this Global Security 

following such 

decrease or increase

	
      

	
Signature of

authorized signatory 

of Trustee

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

 

 

 

A-12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]